ResMed Inc.

ResMed’s economic engine is strengthening: it sells clinically important sleep and respiratory devices, masks and accessories, then complements them with connected-care tools and recurring residential-care software. The core is growing, not showing signs of broad deterioration. Ticker: RMD; NYSE trading currency: USD. Most recent financial data used: nine months ended March 31, 2026.

Sleep and Breathing Health products generated USD 3685900000 in nine-month revenue, up 10.9% year over year; Residential Care Software generated USD 503896000, up 6.2%. Total revenue rose 10.3% to USD 4189796000. The devices and masks are the much larger engine; software adds subscription-like revenue and workflow integration with care providers. Gross profit grew faster than sales, to USD 2590520000, and operating income rose to USD 1438003000—evidence that growth is converting into improved economics.

The model is broadly win-win: patients gain access to treatment for an underdiagnosed chronic condition, clinicians and home-care providers get tools to manage therapy and workflows, and payers may benefit when effective home treatment avoids more costly care. ResMed earns through product sales and software subscriptions rather than relying on patient distress or opaque financial extraction.

The structural opportunity is substantial, but revenue is not perfectly recurring: device replacement cycles, mask replenishment, diagnosis rates, reimbursement and provider purchasing all matter. Software’s slower growth is worth watching, though it is not currently shrinking. The filings show no broad revenue contraction; they do not, by themselves, establish customer-retention rates or rule out future product displacement.

Track four indicators: Sleep and Breathing Health growth, software growth and retention, gross margin, and operating income growth. On the latest reported period, all but software’s relative growth are clearly supportive; software remains positive, not declining.

ResMed operates in a durable, underpenetrated sleep and respiratory-care market: long-term demand looks favorable, though it is not a monopoly market. Its core is positive-airway-pressure (PAP) devices and masks for obstructive sleep apnea (OSA), complemented by ventilation, diagnostics, connected-care software and residential-care software. The market has shifted from stand-alone equipment toward cloud-connected care and recurring replacement supplies.

A reliable, company-defined consolidated TAM is not disclosed; the opportunity is better understood through the large pool of people with undiagnosed sleep apnea and adjacent respiratory-care needs. Demographics, obesity prevalence, diagnosis and home-based care support growth, while reimbursement and adherence constrain conversion. PAP hardware is relatively concentrated among ResMed, Philips and Fisher & Paykel; broader respiratory devices and care software have more competitors. ResMed’s value chain spans device design and manufacturing, distribution through providers and home-care channels, then software-enabled monitoring and ongoing masks/accessories. Overall, the market is a tailwind, but growth depends on diagnosis and treatment adoption—not prevalence alone. Latest filing reviewed: FY2026 10-K, year ended June 30, 2026.

ResMed has a real but not unassailable moat, built on scale, clinician and equipment-provider relationships, and connected-care tools—not on patents or strong customer lock-in. Overall, the moat appears stable: its software ecosystem supports care workflows and adherence, but does not make switching impossible, while device competition remains meaningful.

The key long-term evidence is whether ResMed continues improving its software-enabled workflow and product ecosystem while retaining provider preference. The 2025 10-K describes its cloud-connected devices and residential-care software; it does not establish that these create exclusive data advantages or prohibit switching.

ResMed’s financial strength is a clear positive: high returns are supported by strong cash generation and a net-cash balance sheet. The latest financial data used is for the nine months ended March 31, 2026.

No apparent earnings-to-cash concern: conversion is strong, and inventory declined from fiscal year-end. Returns are well above ordinary capital costs, though ROE is partly influenced by buybacks. Overall, no balance-sheet red flag is evident; the main financial watchpoints are acquisition goodwill and customer/related-party disclosures.

ResMed has a credible long reinvestment runway, though its incremental returns are better supported by the business’s economics than by a clean reported metric. The latest financial data used are for the year ended June 30, 2025; FY2026 results were not available in the retrieved filings.

Growth can come from wider diagnosis and treatment of sleep apnea, product refreshes, masks and connected-care software, and expansion in respiratory care. These opportunities require ongoing R&D and some capacity investment, but the model does not appear to require heavy capital spending to grow. Acquisitions can extend the platform, though the FY2025 filing described the VirtuOx acquisition as not material. A reasonable qualitative estimate is high-single-digit to low-double-digit organic growth potential; it is not a company-provided forecast.

The company appears able to reinvest retained earnings at attractive rates, but no precise incremental ROIC or implied growth rate can be established from the retrieved data without a consistent, acquisition-adjusted invested-capital series. Signal: LONG.

ResMed remains the category leader: its connected-device ecosystem and scale give it an advantage over Philips and smaller device makers, while implantables and oral appliances are substitutes rather than direct PAP competitors. The latest financial data used here is for the quarter ended March 31, 2026.

ResMed’s growth supports continued competitive strength, but it does not prove recent market-share gains: no current, comparable share series was available. Philips remains the key execution variable. ResMed merits further research; its relative valuation versus peers is unscored by evidence here because synchronized current multiples were unavailable.

Conclusion: broadly aligned, but not owner-operator aligned. ResMed’s widely held structure avoids a controlling shareholder, while management’s relatively limited ownership means alignment relies more on board oversight and compensation design than on founders’ capital being at risk.

The FY2026 10-K reports 144,252,306 shares outstanding as of August 10, 2026, but defers detailed director, executive ownership, compensation, and independence disclosures to the proxy statement. I therefore can’t substantiate exact insider ownership, succession depth, or whether recent insider trades were net buying or selling—and won’t infer trade prices relative to today’s share price. Large institutional holders such as Vanguard and BlackRock are principally index managers, not evidence of a distinct investment thesis or active stewardship.

ResMed’s history of dividends and share repurchases supports a shareholder-return orientation. I see no basis here to claim a regulatory action against senior leadership; that is not the same as confirming none exists. Overall, capital allocation appears shareholder-conscious, with limited evidence of meaningful management “skin in the game.” Latest filing used: FY2026, year ended June 30, 2026.

ResMed’s management appears competent and aligned with the business, with no major integrity red flags in the filings reviewed; the main caveat is that acquisition returns are not easy to assess from reported results alone. Capital allocation balances product development and software acquisitions with dividends and share repurchases. Its acquisitions have strategic fit, but I would not treat that as proof of exceptional returns. Execution has been strong: the company continued growing its core business and software operations through changing market conditions. The FY2025 10-K reports no financial-statement restatement and no disagreement with its auditors. The FY2025 10-K and the 10-Q for the quarter ended March 31, 2026 disclose legal proceedings, but do not indicate management expects them to materially affect the business. Latest financial data reviewed: March 31, 2026. Overall signal: HIGH.

ResMed looks fairly valued, not obviously cheap at the supplied USD 35.49B market cap. My estimated present intrinsic value is about USD 34B; the business is strong, but the current price already assumes continued growth.

At USD 252.32 per share, the supplied trailing P/E of 24.2x is broadly consistent with FY2026 net income of USD 1.52B and a market cap of USD 35.49B. I assume roughly 8% annual earnings growth and a 23x exit multiple over five years. That produces an estimated 2031 market cap near USD 53B; discounted at 10%, it implies present value around USD 33B–34B. The embedded growth is plausible given the supplied FY2023–FY2026 revenue increase from USD 4.22B to USD 5.65B, but the valuation offers little margin for a sustained slowdown. The FY2025 10-K describes structural market opportunities, but does not provide a specific multi-year earnings target; therefore, the modeled outcome is not a claim that management guidance will be met.

On liquidation, FY2026 supplied figures show USD 6.59B stockholders’ equity and USD 3.22B tangible book value, with USD 1.47B cash against USD 0.83B debt. Tangible book is a rough upper reference, not a likely recovery estimate: asset-sale discounts and wind-down costs could reduce proceeds. The anomalous 104% dividend yield in the live data is inconsistent with the supplied 23% payout ratio and is not used.

ResMed has a credible decade-long compounding runway; at today’s price, 2–3x over 10 years is plausible if its moat holds, but should come from earnings growth, not assumed multiple expansion. The latest financial data used here is FY2026, ended June 30, 2026.

Its advantage is a broad sleep and respiratory franchise connected to cloud-based tools that help clinicians manage patients and support therapy adherence. Reinvestment in product development, software, and adjacent areas such as restless legs syndrome can extend that position. The FY2026 10-K confirms the June 2026 Noctrix Health acquisition, but it is too early to know whether it will earn attractive incremental returns.

The moat is likely to remain relevant over the next decade and potentially longer: sleep-disordered breathing is a durable health need, though therapies and care models may change. The main erosion risks are credible substitutes, lower-cost competition, and advances in treatments that reduce demand for devices. A thesis-breaking signal would be sustained deterioration in device and mask demand alongside falling adherence or gross margins—not a temporary share-price decline. Current valuation leaves less room for weak execution.

ResMed’s permanent-impairment risk is low: the main threat is lasting displacement of its sleep-therapy franchise, not ordinary volatility in growth, currencies, or reimbursement.

The most consequential scenario is an effective alternative to CPAP becoming widely adopted and materially reducing device demand. That would hit the business’s core; I assess the probability over a 5–10-year horizon as low, though the impact would be high. Product-quality or safety failures causing a broad recall could also damage trust and invite regulatory action, but the filings reviewed do not establish such a failure as a current thesis-level concern.

Competition, reimbursement changes, tariffs, supply interruptions, and foreign-exchange movements can affect results, but appear more like uncertainty unless they become persistent and structurally weaken demand or margins. Financial risk is low: at March 31, 2026, ResMed reported USD 1660513000 in cash and cash equivalents versus USD 664096000 in short- and long-term debt. No material governance red flag is evident in the reviewed filings; this is not proof that none exists.

Overall signal: LOW. Financial data through March 31, 2026.

TRACK — excellent franchise, but only a modest prospective return at today’s price

ResMed is a high-quality, financially resilient business with a credible long-term growth runway. At a market capitalization of USD 35490000000, however, the base-case USD 53000000000 market cap in 2031 implies roughly 8.4% annualized market-cap growth over five years, before dividends. That is positive, but not enough margin of safety for a BUY given the valuation depends on sustained earnings growth and a 23x 2031 earnings multiple.

The latest financial data provided is FY2026. It shows revenue of USD 5650000000 and net income of USD 1520000000, with cash of USD 1469234048 against debt of USD 825918976. These support the view that financial impairment risk is low. The franchise’s scale, provider relationships, and connected-care capabilities underpin durable returns, though they do not eliminate competition or make customers captive.

The strongest argument against owning: PAP therapy could face durable displacement if alternative treatments materially reduce reliance on devices. A further valuation risk is that earnings growth or the assumed exit multiple falls short of the base case; either would weaken already modest expected returns.

Action: Track and wait for a better entry or stronger evidence of durable growth. Existing holders should hold, not add aggressively: the business thesis remains intact, but the current price offers limited downside protection. This is not a load-the-truck opportunity.

Further research: Verify FY2026 results against the company’s filing; assess current market-share trends and the commercial impact of alternative sleep-apnea treatments; stress-test the valuation at lower growth and exit multiples.